Shree Ram Proteins Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 3/6

Shree Ram Proteins şirketinin toplam hissedar öz sermayesi ₹464.9M ve toplam borcu ₹369.4M olup, bu da borç-öz sermaye oranını 79.5% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla ₹982.6M ve ₹517.7M dir.

Anahtar bilgiler

79.5%

Borç/özkaynak oranı

₹369.40m

Borç

Faiz karşılama oranı	n/a
Nakit	₹970.00k
Eşitlik	₹464.91m
Toplam yükümlülükler	₹517.65m
Toplam varlıklar	₹982.56m

Son finansal sağlık güncellemeleri

These 4 Measures Indicate That Shree Ram Proteins (NSE:SRPL) Is Using Debt Extensively

Feb 28

These 4 Measures Indicate That Shree Ram Proteins (NSE:SRPL) Is Using Debt Reasonably Well

Mar 29

Recent updates

These 4 Measures Indicate That Shree Ram Proteins (NSE:SRPL) Is Using Debt Extensively

Feb 28

Is Shree Ram Proteins (NSE:SRPL) A Risky Investment?

Aug 02

Shree Ram Proteins (NSE:SRPL) Has A Pretty Healthy Balance Sheet

Feb 22

Is Shree Ram Proteins (NSE:SRPL) A Risky Investment?

Nov 23

Does Shree Ram Proteins (NSE:SRPL) Have A Healthy Balance Sheet?

Jul 14

These 4 Measures Indicate That Shree Ram Proteins (NSE:SRPL) Is Using Debt Reasonably Well

Mar 29

Calculating The Fair Value Of Shree Ram Proteins Limited (NSE:SRPL)

Dec 11

Shree Ram Proteins (NSE:SRPL) Seems To Use Debt Quite Sensibly

Nov 06

These 4 Measures Indicate That Shree Ram Proteins (NSE:SRPL) Is Using Debt Extensively

Jun 19

Here's Why Shree Ram Proteins (NSE:SRPL) Has A Meaningful Debt Burden

Feb 24

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: SRPL 'nin kısa vadeli varlıkları ( ₹920.1M ) kısa vadeli yükümlülüklerini ( ₹413.8M ) aşıyor.

Uzun Vadeli Yükümlülükler: SRPL şirketinin kısa vadeli varlıkları ( ₹920.1M ) uzun vadeli yükümlülüklerini ( ₹103.9M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: SRPL 'nin net borç/öz sermaye oranı ( 79.2% ) yüksek olarak değerlendiriliyor.

Borcun Azaltılması: SRPL 'nin borç/öz sermaye oranı son 5 yılda 97.9% seviyesinden 79.5% seviyesine düştü.

Borç Kapsamı: SRPL 'nin borcu işletme nakit akışı ( 1.6% ) tarafından iyi bir şekilde karşılanmıyor.

Faiz Kapsamı: SRPL şirketinin borçlarına ilişkin faiz ödemelerinin EBIT tarafından iyi bir şekilde karşılanıp karşılanmadığını belirlemek için yeterli veri yok.

Shree Ram Proteins Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 3/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

These 4 Measures Indicate That Shree Ram Proteins (NSE:SRPL) Is Using Debt Extensively

Is Shree Ram Proteins (NSE:SRPL) A Risky Investment?

Shree Ram Proteins (NSE:SRPL) Has A Pretty Healthy Balance Sheet

Is Shree Ram Proteins (NSE:SRPL) A Risky Investment?

Does Shree Ram Proteins (NSE:SRPL) Have A Healthy Balance Sheet?

These 4 Measures Indicate That Shree Ram Proteins (NSE:SRPL) Is Using Debt Reasonably Well

Recent updates

First quarter 2025 earnings released: ₹0.02 loss per share (vs ₹0.01 profit in 1Q 2024)

Full year 2024 earnings released: ₹0.45 loss per share (vs ₹0.18 profit in FY 2023)

New minor risk - Share price stability

New major risk - Revenue and earnings growth

Now 22% overvalued after recent price rise

Now 24% overvalued after recent price rise

These 4 Measures Indicate That Shree Ram Proteins (NSE:SRPL) Is Using Debt Extensively

Less than half of directors are independent

Shree Ram Proteins Limited Announces the Resignation of Jaykumar Deepakbhai Khatnani as Independent Director

New minor risk - Share price stability

Second quarter 2024 earnings released: ₹0.09 loss per share (vs ₹0.048 profit in 2Q 2023)

Shree Ram Proteins Limited to Report Q2, 2024 Results on Nov 08, 2023

Investor sentiment deteriorates as stock falls 15%

Investor sentiment improves as stock rises 16%

Shree Ram Proteins Limited, Annual General Meeting, Aug 14, 2023

Is Shree Ram Proteins (NSE:SRPL) A Risky Investment?

Less than half of directors are independent

Full year 2023 earnings released: EPS: ₹0.18 (vs ₹0.29 in FY 2022)

Investor sentiment deteriorates as stock falls 16%

Investor sentiment deteriorates as stock falls 15%

Investor sentiment improves as stock rises 17%

Full year 2023 earnings released: EPS: ₹1.79 (vs ₹2.87 in FY 2022)

Investor sentiment improves as stock rises 16%

Chairman & MD recently sold ₹15m worth of stock

Chairman & MD recently sold ₹22m worth of stock

Shree Ram Proteins (NSE:SRPL) Has A Pretty Healthy Balance Sheet

Investor sentiment deteriorates as stock falls 17%

Chairman & MD recently sold ₹4.9m worth of stock

Third quarter 2023 earnings released: EPS: ₹0.25 (vs ₹0.56 in 3Q 2022)

Chairman & MD recently sold ₹2.0m worth of stock

Investor sentiment deteriorated over the past week

Non Executive Director recently sold ₹7.3m worth of stock

Non Executive Director recently bought ₹40m worth of stock

Insider recently sold ₹2.4m worth of stock

Is Shree Ram Proteins (NSE:SRPL) A Risky Investment?

Investor sentiment improved over the past week

Insider recently sold ₹1.7m worth of stock

Chairman & MD recently bought ₹2.4m worth of stock

Second quarter 2023 earnings released: EPS: ₹0.48 (vs ₹0.77 in 2Q 2022)

Less than half of directors are independent

Chairman & MD recently bought ₹1.6m worth of stock

Investor sentiment deteriorated over the past week

Promoter & Whole-Time Director recently sold ₹10m worth of stock

Promoter & Whole-Time Director recently sold ₹3.2m worth of stock

Promoter & Whole-Time Director recently sold ₹2.8m worth of stock

Investor sentiment deteriorated over the past week

Shree Ram Proteins Limited, Annual General Meeting, Jul 18, 2022

Does Shree Ram Proteins (NSE:SRPL) Have A Healthy Balance Sheet?

Promoter & Whole-Time Director recently sold ₹11m worth of stock

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Chairman & MD recently sold ₹4.5m worth of stock

Investor sentiment deteriorated over the past week

Chairman & MD recently sold ₹2.8m worth of stock

Full year 2022 earnings released: EPS: ₹2.87 (vs ₹0.39 in FY 2021)

Chairman & MD recently sold ₹3.7m worth of stock

These 4 Measures Indicate That Shree Ram Proteins (NSE:SRPL) Is Using Debt Reasonably Well

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Investor sentiment deteriorated over the past week

Calculating The Fair Value Of Shree Ram Proteins Limited (NSE:SRPL)

Investor sentiment improved over the past week

Shree Ram Proteins (NSE:SRPL) Seems To Use Debt Quite Sensibly

Second quarter 2022 earnings released: EPS ₹0.77 (vs ₹1.27 loss in 2Q 2021)

These 4 Measures Indicate That Shree Ram Proteins (NSE:SRPL) Is Using Debt Extensively

Full year 2021 earnings released: EPS ₹0.39 (vs ₹1.22 in FY 2020)

Here's Why Shree Ram Proteins (NSE:SRPL) Has A Meaningful Debt Burden

Third quarter 2021 earnings released: ₹0.16 loss per share (vs ₹0.22 loss in 3Q 2020)

New 90-day high: ₹37.35

Shree Ram Proteins Limited Announces Board Changes